in vitro News and Research

RSS

Hepatitis C antivirals synergize with remdesivir to inhibit SARS-CoV-2 in vitro

A new study sheds light on the potential of drug combinations to stem viral transmission and treat patients with COVID-19. It also shows that four drugs used to treat hepatitis C synergize with remdesivir to make it up to ten times more effective at inhibiting SARS-CoV-2 in cell cultures.

30 Apr 2021

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

Researchers in the Republic of Korea (South Korea), The Netherlands, and South Africa have demonstrated the potential of the monoclonal antibody CT-P59 as an effective therapeutic for coronavirus disease 2019 (COVID-19) caused by the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

29 Apr 2021

Potent monoclonal antibody shows promise against emerging SARS-CoV-2 variants of concern

In a new study currently available on the bioRxiv* preprint server, a group of US-based researchers developed a panel of neutralizing monoclonal antibodies against SARS-CoV-2 that can block viral attachment to cells – and pinpointed a specific one that can potently neutralize all tested variants of concern.

28 Apr 2021

Scientists identify blood cells most likely to be targeted by HIV during a real-life infection

In the 40-some years since the beginning of the HIV/AIDS epidemic, scientists have learned a lot about the virus, the disease, and ways to treat it. But one thing they still don't completely understand is which exact cells are most susceptible to HIV infection.

28 Apr 2021

Scientists design 'smart' cellular biosensors for detecting SARS-CoV-2 spike

New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

28 Apr 2021

Researchers design "nanotraps" to capture and destroy SARS-CoV-2 viruses

Researchers at the Pritzker School of Molecular Engineering at the University of Chicago have designed a completely novel potential treatment for COVID-19: nanoparticles that capture SARS-CoV-2 viruses within the body and then use the body's own immune system to destroy it.

27 Apr 2021

Drug cocktail can effectively activate and expand muscle stem cells

Skeletal muscle – the type of muscle that attaches to bones and enables movement – is the most abundant tissue in the human body.

27 Apr 2021

Nanobodies neutralize SARS-CoV-2 in pre-clinical model

A team of Australian researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI), the Doherty Institute, and the Kirby Institute have identified neutralizing nanobody cocktails that block the SARS-CoV-2 virus from entering cells in pre-clinical models.

27 Apr 2021

Study reveals a hidden role of circulating microRNA as a driver of SARS-CoV-2 infection

In a methodological tour-de-force study, a large group of researchers from the USA and the United Kingdom analyzed patient transcriptomic data in-depth and discovered a circulating microRNA (miR-2392) that is directly implicated in the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) machinery during the infection process.

26 Apr 2021

Researchers examine potential SARS-CoV-2 antivirals using a drug repurposing library

A new study deals with the screening of the Drug Repurposing Hub (DRH) library for identifying small compounds which are capable of inhibiting SARS-CoV-2 using both in vitro and in vivo experimental studies. These molecules could be used for designing a novel therapeutic system against SARS-CoV-2 infection.

26 Apr 2021

Recombinant protein vaccine fails expectations for SARS-CoV-2 neutralization

New interim results of a phase 1-2 clinical trial published in The Lancet Infectious Diseases tested the safety and effectiveness of an adjuvanted recombinant protein vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) called CoV2 preS dTM.

26 Apr 2021

High dose of vitamin D does not have a beneficial effect on moderate or severe COVID-19 patients

Can a high dose of vitamin D administered on admission to hospital improve the condition of patients with moderate or severe COVID-19? The answer is no, according to a Brazilian study published in the Journal of the American Medical Association.

23 Apr 2021

Celastrol shows potential anti-SARS-CoV-2 activity

A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.

23 Apr 2021

Impact of proposed law would increase regulatory oversight of certain diagnostic tests

Legislation currently under consideration in the U.S. Congress would increase regulatory oversight of certain diagnostic tests, and a new study by researchers at Massachusetts General Hospital (MGH) and colleagues from several other institutions demonstrates that its potential impact will depend on key details in the bill's final language.

22 Apr 2021

Experts to present latest research on aging and longevity at the 8th Aging Research & Drug Discovery Meeting

Scheibye-Knudsen Lab, University of Copenhagen and Deep Longevity are excited to reveal the speakers for the 8th Aging Research & Drug Discovery Meeting, the largest scientific academic, and industry conference that will transpire on August 31 - September 3, 2021, on-site at the Ceremonial Hall, University of Copenhagen, and online.

22 Apr 2021

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

The SARS-CoV-2 B.1.1.7 variant, also called the UK variant, was identified in London as well as in Southeast and East of England in December 2020. Since its emergence, the UK variant has undergone several mutations that have been said to have altered its infectivity and transmissibility in the community. The B.1.1.7 variant is defined by 17 mutations, several of which are located in the SARS-CoV-2 spike protein that mediates viral attachment and entry into human cells.

21 Apr 2021

Interfering RNA nanoparticles could be a potential COVID-19 therapy

Study shows lipid nanoparticle-based siRNA is potent in suppressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – in cells as well as in mice models.

21 Apr 2021

Researchers develop a new method for the detection and evolution of kidney cancer

The research groups Mintota and Photochemistry Reactivity Group of the faculties of Chemistry and Pharmacy of the University of Valencia have developed a method for the detection and evolution of kidney cancer through urine and the dispersion of gold nanoparticles, in what is the first system that will provide reliable information on the existence and progress of this pathology.

21 Apr 2021

SARS-CoV-2-associated ssRNAs trigger inflammation and immunity via toll-like receptors

Severe COVID-19 causes sepsis-like manifestations, intense lung injury, and multi-organ failure, all associated with the overproduction of pro-inflammatory cytokines. This "cytokine storm" directly correlates with poor prognosis in this subgroup of patients.

21 Apr 2021

FDA takes steps to add molecular tests using pooled nasal specimens in serial testing program

Today, the U.S. Food and Drug Administration took steps to further facilitate the authorization of molecular tests for screening asymptomatic individuals using pooled anterior nasal respiratory specimens in serial testing programs.

20 Apr 2021

in vitro News and Research

Hepatitis C antivirals synergize with remdesivir to inhibit SARS-CoV-2 in vitro

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

Potent monoclonal antibody shows promise against emerging SARS-CoV-2 variants of concern

Scientists identify blood cells most likely to be targeted by HIV during a real-life infection

Scientists design 'smart' cellular biosensors for detecting SARS-CoV-2 spike

Researchers design "nanotraps" to capture and destroy SARS-CoV-2 viruses

Drug cocktail can effectively activate and expand muscle stem cells

Nanobodies neutralize SARS-CoV-2 in pre-clinical model

Study reveals a hidden role of circulating microRNA as a driver of SARS-CoV-2 infection

Researchers examine potential SARS-CoV-2 antivirals using a drug repurposing library

Recombinant protein vaccine fails expectations for SARS-CoV-2 neutralization

High dose of vitamin D does not have a beneficial effect on moderate or severe COVID-19 patients

Celastrol shows potential anti-SARS-CoV-2 activity

Impact of proposed law would increase regulatory oversight of certain diagnostic tests

Experts to present latest research on aging and longevity at the 8th Aging Research & Drug Discovery Meeting

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

Interfering RNA nanoparticles could be a potential COVID-19 therapy

Researchers develop a new method for the detection and evolution of kidney cancer

SARS-CoV-2-associated ssRNAs trigger inflammation and immunity via toll-like receptors

FDA takes steps to add molecular tests using pooled nasal specimens in serial testing program

Driving innovation in drug discovery with in vitro biology solutions eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News